Conditional survival in patients with unresectable perihilar cholangiocarcinoma

HPB (Oxford). 2017 Nov;19(11):966-971. doi: 10.1016/j.hpb.2017.07.004. Epub 2017 Jul 25.

Abstract

Background: Conditional survival is the life expectancy from a point in time for a patient who has survived a specific period after presentation. The aim of the study was to estimate conditional survival for patients with unresectable perihilar cholangiocarcinoma.

Methods: Patients with unresectable perihilar cholangiocarcinoma from two academic hospitals in the Netherlands between 2002 and 2012 were assessed. A multivariable Cox proportional hazards analysis was performed to identify risk factors associated with overall survival. Survival was estimated using the Kaplan-Meier method to evaluate factors associated with overall survival.

Results: In total, 572 patients were included. Overall survival was 42% at one year and 6% at three years. The conditional chance of surviving three years was 15% at 1 year and increased to 38% at 2 years. Independent poor prognostic factors for overall survival were age ≥65 years, tumor size >3 cm on imaging, bilirubin levels (>250 μmol/L), CA19-9 level at presentation (>1000 U/ml), and suspected distant metastases on imaging. The conditional survival of patients with and without these prognostic factors was comparable after patients survived the first two or more years.

Conclusion: The conditional chance of surviving for patients with unresectable perihilar cholangiocarcinoma increases with time. Poor prognostic factors become less relevant once patients have survived two years.

MeSH terms

  • Aged
  • Bile Duct Neoplasms / blood
  • Bile Duct Neoplasms / mortality
  • Bile Duct Neoplasms / pathology
  • Bile Duct Neoplasms / therapy*
  • Bilirubin / blood
  • CA-19-9 Antigen / blood
  • Chi-Square Distribution
  • Contraindications, Procedure
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Klatskin Tumor / blood
  • Klatskin Tumor / mortality
  • Klatskin Tumor / secondary
  • Klatskin Tumor / therapy*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Tumor Burden

Substances

  • CA-19-9 Antigen
  • Bilirubin